Filtered By:
Condition: Hypertension
Education: Learning
This page shows you your search results in order of date.
Order by Relevance | Date
Total 201 results found since Jan 2013.
COVID-19 ’ s Impact on Heart Health Still Confounds Doctors
(ST. LOUIS) — Firefighter and paramedic Mike Camilleri once had no trouble hauling heavy gear up ladders. Now battling long COVID, he gingerly steps onto a treadmill to learn how his heart handles a simple walk.
“This is, like, not a tough-guy test so don’t fake it,” warned Beth Hughes, a physical therapist at Washington University in St. Louis.
[time-brightcove not-tgx=”true”]
Somehow, a mild case of COVID-19 set off a chain reaction that eventually left Camilleri with dangerous blood pressure spikes, a heartbeat that raced with slight exertion, and episodes of intense chest pain...
Source: TIME: Health - August 10, 2023 Category: Consumer Health News Authors: Lauran Needgaard/ Associated Press Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news
Prediction of short-term atrial fibrillation risk using primary care electronic health records
Conclusions
FIND-AF, a machine learning algorithm applicable at scale in routinely collected primary care data, identifies people at higher risk of short-term AF.
Source: Heart - June 26, 2023 Category: Cardiology Authors: Nadarajah, R., Wu, J., Hogg, D., Raveendra, K., Nakao, Y. M., Nakao, K., Arbel, R., Haim, M., Zahger, D., Parry, J., Bates, C., Cowan, C., Gale, C. P. Tags: Open access, Editor's choice Arrhythmias and sudden death Source Type: research
Predicting new-onset post-stroke depression from real-world data using machine learning algorithm
DiscussionMachine learning models can provide as potential predictive tools for PSD and important factors are identified to alert clinicians for early detection of depression in high-risk stroke patients.
Source: Frontiers in Psychiatry - June 19, 2023 Category: Psychiatry Source Type: research
Association of brain microbleeds with risk factors, cognition, and MRI markers in MESA
DISCUSSION: Results suggest differing associations for lobar versus deep locations. Sensitive microbleed quantification will facilitate future longitudinal studies of their potential role as an early indicator of vascular pathology.PMID:37289978 | DOI:10.1002/alz.13346
Source: The Journal of Alzheimers Association - June 8, 2023 Category: Psychiatry Authors: Paul N Jensen Tanweer Rashid Jeffrey B Ware Yuhan Cui Colleen M Sitlani Thomas R Austin W T Longstreth Alain G Bertoni Elizabeth Mamourian R Nick Bryan Ilya M Nasrallah Mohamad Habes Susan R Heckbert Source Type: research
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Introducing Cochrane Heart, Stroke and Circulation
Stroke, heart disease, hypertension and peripheral vascular diseases are leading global causes of mortality and morbidity. As the population ages and these conditions become more common in low-income countries, the need for an integrated response has become increasingly clear.The newHeart, Stroke and Circulation Thematic Groupaims to bring together experts from across all four topics to foster collaboration between researchers in different fields while providing comprehensive reviews on cutting-edge topics related to stroke, heart disease, hypertension, and peripheral vascular diseases. A collaborative effortThrough th...
Source: Cochrane News and Events - May 10, 2023 Category: Information Technology Authors: Muriah Umoquit Source Type: news
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Development of rapid and effective risk prediction models for stroke in the Chinese population: a cross-sectional study
Conclusion
The five machine learning models all had good predictive and discriminatory performance for stroke. The performance of RF and XGBoost was slightly better than that of LR, which was easier to interpret and less prone to overfitting. This work provides a rapid and accurate tool for stroke risk assessment, which can help to improve the efficiency of stroke screening medical services and the management of high-risk groups.
Source: BMJ Open - March 1, 2023 Category: General Medicine Authors: Qiu, Y., Cheng, S., Wu, Y., Yan, W., Hu, S., Chen, Y., Xu, Y., Chen, X., Yang, J., Chen, X., Zheng, H. Tags: Open access, Public health Source Type: research
Using Artificial Intelligence to Develop a Multivariate Model with a Machine Learning Model to Predict Complications in Mexican Diabetic Patients without Arterial Hypertension (National Nested Case-Control Study): Metformin and Elevated Normal Blood Pressure Are Risk Factors, and Obesity Is Protective
In conclusion, the results we have obtained show that artificial intelligence is a powerful and feasible tool to use for this type of study. However, we suggest that more studies be conducted to verify and elaborate upon our findings.PMID:36846513 | PMC:PMC9949947 | DOI:10.1155/2023/8898958
Source: Cancer Control - February 27, 2023 Category: Cancer & Oncology Authors: Sergio A Zaizar-Fregoso Agustin Lara-Esqueda Carlos M Hern ández-Suarez Josuel Delgado-Enciso Arturo Garcia-Nevares Luis M Canseco-Avila Jose Guzman-Esquivel Iram P Rodriguez-Sanchez Margarita L Martinez-Fierro Gabriel Ceja-Espiritu Hector Ochoa-D íaz-L Source Type: research
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
The U.S. Still Doesn ’ t Have Good COVID-19 Data. Here ’ s Why That ’ s a Problem
Check the COVID-19 Data Tracker from the U.S. Centers for Disease Control and Prevention (CDC), and you’ll get a rundown of the latest case numbers, hospitalizations, and deaths. Those categories might seem straightforward, but the data, say many experts, are telling us a lot less than we think they are.
That’s because it’s getting increasingly difficult to parse who is hospitalized or dies from COVID-19, and who is hospitalized or dies from another reason but with COVID-19. Across the U.S., “COVID-19 hospitalizations” represent all kinds of patients: those who need hospital-level care for sev...
Source: TIME: Health - January 30, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
What to Know if Your Doctor Put You on Statins to Lower Cholesterol
High cholesterol is a prime example of having too much of a good thing. Our bodies naturally make this substance in the liver and then transport it throughout the body for multiple functions, including hormone regulation, cell tissue regeneration, and vitamin absorption. When the system is working well, cholesterol can boost overall health. But when a certain type called low-density lipoprotein—LDL, sometimes dubbed the “bad” kind—is overproduced, not only does it block the “good” kind called high-density lipoprotein (HDL), but it can also begin to accumulate in the arteries and form thi...
Source: TIME: Health - January 25, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news
